This week, join our webinar with Michelle Mellion, MD, a senior medical director working on therapies for rare neuromuscular diseases at Fulcrum Therapeutics. Many of you volunteered for a study in 2018 and early 2019 to help Fulcrum study various methods to track the progression of muscle degeneration. This was a vitally important study to help the company design the current ReDUX4 clinical trial of the first compound to target the root genetic cause of FSHD. We’re delighted that Fulcrum is reporting back to our community about what they learned from your invaluable participation!
Dr. Mellion graduated from Colgate University with honors in molecular biology and Wake Forest University Medical School. She went on to complete her internship in medicine, residency in neurology and fellowship in clinical neurophysiology at Brown. After approximately a decade on the faculty at the Warren Alpert Medical School/Brown University where she conducted her own grant funded research, served as director of the clinical neurophysiology fellowship, neurology residency program and was an attending physician at the MDA neuromuscular clinic as well as at her own private general neurology clinic, Michelle decided to expand her scope of expertise in the pharmaceutical industry. She transitioned from academia to clinical development at Biogen where she worked on the remyelination program as well as contributed to the development of novel biomarkers. She then co-led the pain program at Vertex Pharmaceuticals. Dr. Mellion has authored and co-authored over 20 publications on her personal research as well as in programs to which she has contributed in industry.
Every Thursday, at 1:00 pm ET, we are hosting our “FSHD Society Sequester Camp” webinar series, which will run every week at the same time for as long as it’s needed. Anyone can join from anywhere for free. We’ll be sharing information, resources, and social support. For your personalized link to join the webinar, click on the link below.
Please note that we will be recording these webinars, and will have information and updates on a regular basis.